A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer

Background: GV1001 is a human telomerase peptide vaccine that induces a CD4/CD8 T-cell response against cancer cells, thereby affording an immunological anti-tumor effect. Here, we evaluated the efficacy and safety of GV1001 in combination with chemotherapy in patients with metastatic colorectal can...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sejin, Kim, Bum Jun, Kim, Ilhwan, Kim, Jung Han, Kim, Hee Kyung, Ryu, Hyewon, Choi, Dae Ro, Hwang, In Gyu, Song, Hunho, Kwon, Jung Hye, Jung, Joo Young, Han, Boram, Zang, Dae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899359/
https://www.ncbi.nlm.nih.gov/pubmed/35281880
http://dx.doi.org/10.7150/jca.70385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899359/
https://www.ncbi.nlm.nih.gov/pubmed/35281880
http://dx.doi.org/10.7150/jca.70385

Ejemplares similares